Minodronic acid is a third-generation bisphosphonate drug.

It is approved for use in Japan for the treatment of osteoporosis.

[1] Its mechanism of action involves inhibition of farnesyl pyrophosphate synthase activity.

[2] This drug article relating to the musculoskeletal system is a stub.

You can help Wikipedia by expanding it.